SCHEMBL12656246

SCHEMBL12656246

C=CCNc1c(O)cc2c(O)c1C[C@@H](C)CCC(O)[C@@H](C)/C=C(\C)C(OC(N)=O)C(OC)/C=C\C=C(/C)C(=O)N2

nearest known ligand 0.83

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 17/20 0.83
HSP90AB1 P08238 9/20 0.83
PDGFRA P16234 1/20 0.83
ERBB2 P04626 2/20 0.47
ALDH1A1 P00352 1/20 0.45
ESR1 P03372 1/20 0.44
RAF1 P04049 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12655972 1.00 HSP90AA1 (0.83) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
SCHEMBL13221597 0.92 HSP90AA1 (0.88) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL13204564 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL254016 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL13221536 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL12446217 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL254489 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL14748340 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL22496014 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL13199500 0.92 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011060328-A1 COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CANCER INFINITY PHARMACEUTICALS, INC. (US) 2011-05-19 WO disclosed
WO-2010135426-A1 METHODS OF TREATING LIPOSARCOMA INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
WO-2008128063-A1 HYDROQUINONE ANSAMYCIN FORMULATIONS INFINITY DISCOVERY, INC. (US) 2008-10-23 WO disclosed